Thus, de novo T790M mutation may define a special subset of EGFR-mutant NSCLC with favorable prognosis when treated with first-line Osimertinib, which warrants further validation with a large sample size study. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.